• KOL
    • Antiretroviral Therapy
    • Peter Reiss†
    • Peter Reiss†: Influence Statistics

      Peter Reiss†

      Peter Reiss†

      Show email address

      Stichting HIV Monitoring, Amsterdam, the Netherlands | Stichting HIV Monitoring, Amsterdam, Amsterdam, AZ 1105, Netherlands | Department of Internal Medicine, Division of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Peter Reiss†:Expert Impact

      Concepts for whichPeter Reiss†has direct influence:Antiretroviral therapy,Hiv infection,Myocardial infarction,Cardiovascular disease,North america,Hiv infections,Viral load.

      Peter Reiss†:KOL impact

      Concepts related to the work of other authors for whichfor which Peter Reiss† has influence:Antiretroviral therapy,Hiv infection,Human immunodeficiency virus,Infected patients,Viral load,Cardiovascular disease,Highly active.

      KOL Resume for Peter Reiss†

      Year
      2022

      Stichting HIV Monitoring, Amsterdam, the Netherlands

      Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam

      2021

      Amsterdam Institute for Global Health and Development, and HIV Monitoring Foundation, Amsterdam, The Netherlands

      2020

      Amsterdam UMC, Location AMC, University of Amsterdam, Department of Global Health, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Peter Reiss† is among the top experts in the world.
      Concept World rank
      hivassociated cognitive deficits #1
      alternative regimens sets #1
      events anti #1
      infarction hiv #1
      daauptake hcv transmission #1
      zdv didanosine follow #1
      physical hrql higher #1
      virological failure regimen #1
      lpvr nvp #1
      pwh sex #1
      cbf hivinfected patients #1
      test regimen breakfast #1
      nefspecific antibodies #1
      plhiv 75 #1
      nvp p004 #1
      indinavir didanosine #1
      μl 350 cells #1
      fib4 older age #1
      diabetes lipodystrophy #1
      art vacs #1
      stavudine treatment coefficient #1
      implementation ahi strategy #1
      cbf decreased cbf #1
      individuals compared #1
      antiretroviral agents arvs #1
      hypertension hiv1infected patients #1
      logistic models comorbidity #1
      antihypertensive drugs awareness #1
      sustained hiv suppression #1
      pwid personyears #1
      hteam #1
      cmin nelfinavir #1
      orstavudine #1
      hiv test ratios #1
      nvp lipid profiles #1
      200 cells mm³ #1
      people aehi #1
      replicate values sample #1
      patient european union #1
      treatment responses genotype #1
      young adult kilimanjaro #1
      antiretrovirals exposure #1
      fvc hivnegative participants #1
      intermittent art bmd #1
      continuous art bmd #1
      p0751 #1
      hsr treatmentnaive patients #1
      μl higher cd4 #1
      zdv naïve cd4 #1
      cartnaive #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Peter Reiss†

      KOL-Index: 26034

      BACKGROUND: High early mortality in patients with HIV-1 starting antiretroviral therapy (ART) in sub-Saharan Africa, compared to Europe and North America, is well documented. Longer-term comparisons between settings have been limited by poor ascertainment of mortality in high burden African settings. This study aimed to compare mortality up to four years on ART between South Africa, Europe, and North America.

      METHODS AND FINDINGS: Data from four South African cohorts in which patients ...

      Known for North America | South Africa | Antiretroviral Therapy | Art Europe | Early Mortality
      KOL-Index: 20545

      BACKGROUND: Data on prevalence and incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in Rwanda are scarce.

      METHODS: HBV status was assessed at baseline and Month 12, and anti-HCV antibodies at baseline, in a prospective cohort study of HIV-infected patients in Kigali, Rwanda: 104 men and 114 women initiating antiretroviral therapy (ART) at baseline, and 200 women not yet eligible for ART.

      RESULTS: Baseline prevalence of active HBV infection (HBsAg positive), past ...

      Known for Hcv Infection | Art Baseline | Hepatitis Virus Hbv | Kigali Rwanda | Hivinfected Patients
      KOL-Index: 20387

      BACKGROUND: Recommendations have differed nationally and internationally with respect to the best time to start antiretroviral therapy (ART). We compared effectiveness of three strategies for initiation of ART in high-income countries for HIV-positive individuals who do not have AIDS: immediate initiation, initiation at a CD4 count less than 500 cells per μL, and initiation at a CD4 count less than 350 cells per μL.

      METHODS: We used data from the HIV-CAUSAL Collaboration of cohort ...

      Known for Antiretroviral Therapy | Cd4 Count | Art Initiation | 500 Cells | Hiv Diagnosis
      KOL-Index: 19066

      BACKGROUND: Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

      METHODS: The Opportunistic ...

      Known for Cd4 Cell | Prophylaxis Patients | Hiv Infection | Incidence Pcp | Primary Pneumocystis
      KOL-Index: 17723

      CONTEXT: Current guidelines recommend that individuals infected with the human immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents to achieve sustained suppression of viral replication as measured by the plasma HIV-1 RNA assay, in the hopes of achieving prolonged remission of the disease. However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA.

      OBJECTIVE: To compare the virologic effects of various ...

      Known for Nevirapine Zidovudine | Hiv1 Rna | Incas Trial | Triple Drug Therapy | Infected Patients
      KOL-Index: 16331

      Background: We investigated whether CD4:CD8 ratio and CD8 count were prognostic for all-cause, AIDS, and non-AIDS mortality in virologically suppressed patients with high CD4 count.

      Methods: We used data from 13 European and North American cohorts of human immunodeficiency virus-infected, antiretroviral therapy (ART)-naive adults who started ART during 1996-2010, who were followed from the date they had CD4 count ≥350 cells/μL and were virologically suppressed (baseline). We used ...

      Known for Cd8 Ratio | Antiretroviral Therapy | Infected Patients | Immunodeficiency Virus | Cd4 Count
      KOL-Index: 15919

      BACKGROUND: Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovirals and the development of chronic kidney disease in people with initially normal renal function, as measured by estimated glomerular filtration rate (eGFR).

      METHODS: In ...

      Known for Chronic Kidney Disease | Filtration Rate | Estimated Glomerular | Normal Baseline | Positive Individuals
      KOL-Index: 15508

      CONTEXT: The availability of new antiretroviral drugs and formulations, including drugs in new classes, and recent data on treatment choices for antiretroviral-naive and -experienced patients warrant an update of the International AIDS Society-USA guidelines for the use of antiretroviral therapy in adult human immunodeficiency virus (HIV) infection.

      OBJECTIVES: To summarize new data in the field and to provide current recommendations for the antiretroviral management and laboratory ...

      Known for Antiretroviral Treatment | Hiv Infection | Usa Panel | 2008 Recommendations | International Aids Society
      KOL-Index: 15187

      BACKGROUND: Patients with human immunodeficiency virus (HIV) infection and a history of Pneumocystis carinii pneumonia are at high risk for relapse if they are not given secondary prophylaxis. Whether secondary prophylaxis against P. carinii pneumonia can be safely discontinued in patients who have a response to highly active antiretroviral therapy is not known.

      METHODS: We analyzed episodes of recurrent P. carinii pneumonia in 325 HIV-infected patients (275 men and 50 women) in eight ...

      Known for Secondary Prophylaxis | Hiv Infection | Cubic Millimeter | Pneumocystis Carinii | Antiretroviral Therapy Patients
      KOL-Index: 14940

      BACKGROUND: The benefits of combination anti-retroviral therapy (cART) in HIV-positive pregnant women (improved maternal health and prevention of mother to child transmission [pMTCT]) currently outweigh the adverse effects due to cART. As the variety of cART increases, however, the question arises as to which type of cART is safest for pregnant women and women of childbearing age. We studied the effect of timing and exposure to different classes of cART on adverse birth outcomes in a ...

      Known for Gestational Age | Pregnant Women | Cart Hiv | Risk Sga | Newborn Infant
      KOL-Index: 14687

      BACKGROUND: Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted darunavir were associated with increased incidence of cardiovascular disease in people living with HIV.

      METHODS: The prospective Data Collection on Adverse Events of Anti-HIV Drugs ...

      Known for Cardiovascular Disease | Protease Inhibitors | 1000 Personyears | Darunavir Ritonavir | People Hiv
      KOL-Index: 14636

      OBJECTIVES: To estimate the incidence of and risk factors for modifications to first antiretroviral therapy (ART) regimen, treatment interruption and death.

      METHODS: A total of 21 801 patients from 18 cohorts in Europe and North America starting ART on regimens including at least two nucleoside reverse transcriptase inhibitors and boosted protease inhibitor or non-nucleoside reverse transcriptase inhibitor during 2002-2009 were included. Incidence of modifications (change of drug class, ...

      Known for Art Regimen | Risk Factors Modification | Reverse Transcriptase | Protease Inhibitors | Positive Patients
      KOL-Index: 14589

      OBJECTIVES: HIV-infected patients using combination antiretroviral therapy (ART) have an increased cardiovascular risk. We aimed to identify the effects of HIV, ART, and lipodystrophy (LD) on carotid artery intima-media thickness (C-IMT), a surrogate measure of atherosclerosis, and arterial stiffness, a marker of cardiovascular risk.

      DESIGN: Case-control study of 77 HIV-infected men (55 exposed to ART, 22 ART naive, and 23 with LD) and 52 controls.

      METHODS: C-IMT was measured ...

      Known for Arterial Stiffness | Antiretroviral Therapy | Carotid Intima | Hiv Art | Cardiovascular Risk

      Key People For Antiretroviral Therapy

      Top KOLs in the world
      #1
      Andrew N Phillips†
      antiretroviral therapy viral load hiv infection
      #2
      Jens Dilling Lundgren
      antiretroviral therapy hiv infection viral load
      #3
      Peter Reiss†
      antiretroviral therapy hiv infection myocardial infarction
      #4
      David A Cooper
      antiretroviral therapy hiv infection viral load
      #5
      Joseph J Eron
      antiretroviral therapy united states hiv infection
      #6
      Douglas D Richman†
      antiretroviral therapy hiv infection human immunodeficiency virus

      Stichting HIV Monitoring, Amsterdam, the Netherlands | Stichting HIV Monitoring, Amsterdam, Amsterdam, AZ 1105, Netherlands | Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, Academic Medical Center, Amsterdam, the Net

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.